Pharmaceutical Non-Active Ingredients TRIZ Cases

A cysteine-mutant antibody links to a TLR agonist via a chemical linker to form an immunoconjugate.

Maleimide linkers attach CIDEs to antibodies, extending half-life and improving targeted delivery.

PST releases bound water via thermal energy for liquid-free granulation, eliminating the energy-intensive drying step.

Sodium lauryl sulfate at specific molar ratios masks bitter drug tastes in thin intraoral films, maintaining rapid dissolution without complex production steps.

Solid amphiphilic compounds maintain tablet hardness while forming liquid crystalline structures that enable prolonged release of lipophilic drugs.

Reversible arylboronic acid conjugation releases proteins in response to pH or reactive oxygen species, preserving native activity.

Liposomal statin formulations encapsulate active ingredients in lipid bilayers to enhance solubility and skin penetration without toxic solvents.

Phase change nanodroplet conjugates use ultrasound to vaporize a gaseous core and release attached therapeutic nanoparticles at a target site.

Polyoxyethylene framework moderates blood concentration to prevent peak-valley phenomena and bradycardia while improving therapeutic stability.

Alcohol-based wet granulation improves compressibility and dissolution of empagliflozin and metformin hydrochloride tablets.

D160S and K196S mutations in Sortase A boost enzymatic activity five-fold, resolving low substrate concentration bottlenecks.

Copolymer coatings resist active ingredient release in neutral environments while dissolving rapidly in acidic gastric conditions.

Reducing hydroxypropyl cellulose viscosity to 1.10–1.95 mPa·s suppresses core particle aggregation while maintaining tablet hardness and disintegration time.

Segmenting the film into active-containing and flexible layers resolves the contradiction between rapid solubility and mechanical strength.